Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN G POTASSIUM versus POLYCILLIN PRB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN G POTASSIUM versus POLYCILLIN PRB.
PENICILLIN G POTASSIUM vs POLYCILLIN-PRB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal: inhibits transpeptidases (penicillin-binding proteins) involved in bacterial cell wall synthesis, leading to cell lysis.
POLYCILLIN-PRB combines ampicillin and probenecid. Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Probenecid inhibits renal tubular secretion of ampicillin, increasing its plasma concentration.
1-4 million units IV every 4-6 hours; maximum 24 million units/day
250-500 mg orally every 6 hours or 500 mg-1 g intramuscularly every 6-8 hours.
None Documented
None Documented
0.5-1 hour in normal renal function; prolonged to 3-10 hours in anuria/end-stage renal disease.
Terminal elimination half-life: 1-1.5 hours in patients with normal renal function; prolonged to 7-10 hours in anuria.
Renal (60-90% as unchanged drug via tubular secretion and glomerular filtration); biliary (minor, <10%); fecal (minimal, <5%).
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; Biliary/fecal: 20-40% as metabolites and unchanged drug.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic